drugset / Trial / NCT05203315

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

NCT05203315

RandomizedSingle-groupOpen-labelTreatment

Summary

This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.

Timeline

Start
2022-01-13
Primary completion
2023-10-04
Completion
2023-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.045 % Topical
Subject halobetasol propionate Small molecule 0.01 % Topical

Indications